FRMD6

Across TCGA pan-cancer cohorts, FRMD6 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FRMD6’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where FRMD6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FRMD6 is over-expressed in tumor, although a few such as OV show the opposite, repressed pattern.

PDAC, LSCC, and OV are the cancer types where FRMD6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FRMD6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	II,III,IV	+0.874	<.001	9	view →
LSCC	Male	II,III,IV	+0.685	<.001	8	view →
OV	All	All	−0.811	.009	2	view →
CCRCC	Male	All	+0.458	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FRMD6–PDAC

Open the PDAC breakdown →